|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Two of 5 patients with BRAF V600E had progression, including 1 GT-UMP with local recurrence and 1 malignant tumor with enlarging residual disease.
|
28834810 |
2017 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Overall, our results suggest that DETD-35 may be useful as a therapeutic or adjuvant agent against BRAF(V600E) mutant and acquired vemurafenib resistance melanoma.Mol Cancer Ther; 15(6); 1163-76.©2016 AACR.
|
27048951 |
2016 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Since the V600E BRAF protein has emerged as an important therapeutic target for cancer, the developed assay should facilitate future BRAF-related basic and clinical studies.
|
27497007 |
2016 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Screening for BRAF c.1799T>A p.V600E is especially useful for those with malignant tumors, because it is one of the most-druggable targets.
|
26360803 |
2016 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We found that gene mutations for EGFR (P = .02) and ALK (P < .001) were associated with cancer diagnosis at a younger age, and a similar trend existed for ERBB2 (P = .15) and ROS1 (P = .10) but not BRAF V600E (P = .43).
|
26720421 |
2016 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Two patients with treatment-refractory high-grade colorectal neuroendocrine tumors harboring BRAF(V600E) exhibited rapid and durable response to combined BRAF-MEK inhibition, providing the first clinical evidence of efficacy in this aggressive tumor type.Cancer Discov; 6(6); 594-600.
|
27048246 |
2016 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Therefore, in cases of indeterminate FNA with unclassifiable atypical cells BRAF (V600E) mutated, the possibility of a localization of hystiocytosis or a secondary thyroid malignancy should be taken into account.
|
26782803 |
2016 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Using patient-derived (V600E)BRAF melanoma cells, we found that low-glutamine-induced histone hypermethylation resulted in cancer cell dedifferentiation and resistance to BRAF inhibitor treatment, which was largely mediated by methylation on H3K27, as knockdown of the H3K27-specific demethylase KDM6B and the methyltransferase EZH2 respectively reproduced and attenuated the low-glutamine effects in vitro and in vivo.
|
27617932 |
2016 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Although the presence of the BRAF V600E mutation is indicative of a sporadic cancer, up to 30% to 50% of colorectal carcinomas with MLH1 promoter hypermethylation will lack a BRAF mutation.
|
27438990 |
2016 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The purpose of this study was to evaluate the feasibility of core-needle biopsy with BRAF(V600E) mutation analysis (CNB + BRAF(V600E) ) and to compare the clinical usefulness of CNB + BRAF(V600E) and fine-needle aspiration with BRAF(V600E) mutation analysis (FNA + BRAF(V600E) ) in the diagnosis of thyroid malignancy.
|
26215382 |
2016 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Unlike BRAF(V600E), the most common mutation, K601E is strongly associated with follicular-patterned cancer, particularly with the encapsulated follicular variant of PTC, and may also be found in follicular thyroid carcinomas.
|
26422023 |
2016 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Evidence has also shown that the detection of the BRAF(V600E) mutation in cancer is crucial in order to identify novel avenues for thyroid cancer treatment.Based on the BRAF kinase structure, novel drugs can potentially be designed to target oncogenic BRAF in cancer therapeutics.
|
25961545 |
2015 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience.
|
25353071 |
2015 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study demonstrates the activating BRAF mutation (V600E), which is found in multiple human cancers, is a driver of canine InvTCC, and highlights a urine-based test for quick diagnosis.
|
25767210 |
2015 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
This combinatorial effect was recapitulated in human melanoma-derived cell lines and was restricted to cancers bearing a BRAF(V600E) mutation.
|
25358764 |
2015 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here we show that Sleeping Beauty (SB) transposon-mediated mutagenesis drives melanoma progression in Braf(V600E) mutant mice and identify 1,232 recurrently mutated candidate cancer genes (CCGs) from 70 SB-driven melanomas.
|
25848750 |
2015 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Cytomorphologic features can help select nodules for the BRAF(V600E) mutation test among nodules read as "suspicious for malignancy" on cytology.
|
26187369 |
2015 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We hypothesized it would be more commonly methylated and inactivated in serrated pathway colorectal cancers that are hallmarked by a BRAF V600E mutation and a methylator phenotype, compared to traditional pathway cancers that are BRAF wild type.
|
25613750 |
2015 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Elucidating the spectrum of non-p. V600E BRAF mutations in different malignancies is a first step toward understanding their clinical significance.
|
26386083 |
2015 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We used a polymerase chain reaction-based assay to detect mutations in BRAF (V600E) and in KRAS in 2720 stage III cancer samples, collected prospectively from patients participating in an adjuvant chemotherapy trial (NCCTG N0147).
|
25305506 |
2015 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The mutation BRAF V600E is thought to be a putative prognostic marker of the aggressiveness of several cancers among which is also papillary thyroid cancer.
|
23925579 |
2014 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Braf(V600E)-driven tumors require autophagy and likely autophagy-provided substrates to maintain mitochondrial metabolism and to promote tumor growth, suggesting that autophagy ablation may improve cancer therapy.
|
24860158 |
2014 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Taken together, these results suggest that Cu-chelation therapy could be repurposed to treat cancers containing the BRAF(V600E) mutation.
|
24717435 |
2014 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Recently, increasing evidences indicate that BRAF((V600E)) mutation is a specific molecular feature and driver of the serrated pathway, and proximal serrated polyps with BRAF((V600E)) mutation have a high risk of progression to malignancy.
|
25550768 |
2014 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E)-mutated DNA was quantified in plasma samples and in cancer sections by quantitative real-time polymerase chain reaction (qPCR).
|
24858900 |
2014 |